Hengrui shr7390 tablet and Baiji Shenzhou bgb-3111 capsule were approved for clinical use
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The clinical application of class 1.1 new drugs of shr7390 tablets entered CFDA drug review center on December 31, 2014, and took a special review channel Shr7390 is a MEK kinase inhibitor developed for cancer Last week, Hengrui just got 6 clinical approvals On February 13, 2015, the clinical application of class 1.1 new drug of bgb-3111 capsule entered the CFDA drug review center and took a special review channel Bgb-3111 is a Btk inhibitor, which is said to have higher selectivity than ibrutinib, the world's first btik inhibitor The preliminary results of the phase I study of bgb-3111 single drug in the treatment of multiple advanced B-cell malignancies were announced at the ash2015 annual meeting of Baiji Shenzhou on December 7.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
